
Kisspeptin
Potential Benefits
- Research confirms kisspeptin as a key regulator of reproductive hormone cascades
- Clinical studies suggest it can stimulate LH and FSH release in both men and women
- Neuroimaging studies indicate potential to enhance brain processing of sexual and emotional stimuli
- May have applications in diagnosing and treating reproductive disorders
- Research suggests potential metabolic regulatory roles
Recommended Starting Dose
1 nmol/kg intravenously (research setting); not established for clinical outpatient use
Based on published research protocols. Not a prescription.
Dosing Protocol
In research settings, kisspeptin-54 has been administered as single IV bolus injections (1-10 nmol/kg) or as continuous infusions. No established outpatient clinical protocol exists. The short half-life necessitates IV administration or development of longer-acting analogs.
DOSING INFORMATION DISCLAIMER: Any dosing information, protocols, or ranges discussed on this site are drawn from published research studies and clinical literature. They are presented for educational reference only and must not be used as self-medication guidance.
Expected Timeline
Phase 1
Hormonal responses (LH surge) occur within minutes to hours of IV administration. This is primarily a research tool at this stage.
Research Status
The regulatory status of peptides can change at any time. Verify current FDA classification and legal status in your jurisdiction before seeking medical consultation about this compound.
Potential Side Effects
- Research compound with limited clinical safety data for therapeutic use
- Injection site reactions
- Potential headache and flushing
- Effects on reproductive hormones require careful monitoring
- Short half-life (minutes) limits practical therapeutic application
- Long-term effects of exogenous administration are unknown
More in Sexual Health

PT-141
Bremelanotide
PT-141 (bremelanotide) is a synthetic melanocortin receptor agonist that acts on the MC3R and MC4R receptors in the central nervous system. Unlike PDE5 inhibitors that act on vascular mechanisms, PT-141 works through the brain's arousal pathways. It is FDA-approved under the brand name Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women.

Gonadorelin
Gonadorelin (GnRH)
Gonadorelin is a synthetic version of gonadotropin-releasing hormone (GnRH), identical to the naturally occurring decapeptide produced by the hypothalamus. It stimulates the anterior pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH). It has FDA-approved diagnostic and therapeutic applications.
Medical Disclaimer
EDUCATIONAL CONTENT ONLY: The peptide information presented on this page is compiled from published scientific literature, peer-reviewed research, and publicly available clinical data. It is provided strictly for educational purposes and does not constitute medical advice, an endorsement of any specific peptide, or a recommendation for treatment. Many peptides discussed on this site have not received FDA approval for human therapeutic use. Some may be under active regulatory review or subject to restrictions on compounding under FDA Section 503A and 503B frameworks. The regulatory status of individual peptides can change at any time. Readers should verify the current legal status of any peptide in their jurisdiction before pursuing further information or consultation. If you are considering peptide therapy, seek guidance from a licensed physician or healthcare provider who specializes in peptide-based treatments and operates within applicable federal and state regulations.